Literature DB >> 21767984

In vivo HPV 16 E5 mRNA: expression pattern in patients with squamous intra-epithelial lesions of the cervix.

Laura Lorenzon1, Francesca Mazzetta, Aldo Venuti, Antonio Frega, Maria Rosaria Torrisi, Deborah French.   

Abstract

BACKGROUND: Human Papillomavirus (HPV) type 16 E5 is a small protein, which is reported to display transforming activity in vitro and in animal studies. The E5 transcriptional activity, however, has been rarely reported in vivo in literature.
OBJECTIVES: (a) To detect the E5 transcripts in vivo in a population of HPV 16 positive patients with abnormal cytology and (b) to correlate the level of expression to the degree of the cytological lesion. STUDY DESIGN AND METHODS: 250 cytological samples of HPV positive women were obtained and tested for the E6/E7 mRNA expression. Patients were selected if HPV 16 only mRNA positive and with a cytology consistent with low-grade/high-grade squamous intra-epithelial (LSIL/HSIL) lesions. Selected patients were tested for the E5 transcripts by reverse RT PCR, comparing the expression level in vivo with a transfected HPV 16 E5 HaCaT cell line.
RESULTS: 27 HPV 16 E6/E7 mRNA positive LSIL/HSIL patients were selected. 13 out of 17 LSIL patients were tested positive for the E5 mRNA, showing an ample range of positivity. In the HSIL group 7 out of 10 patients were tested positive, displaying lower and more homogeneous levels of expression if compared with the transfected cells.
CONCLUSION: The HPV 16 E5 transcripts levels showed a broad distribution in vivo; the discrepancy was wider in LSIL patients, with HSIL patients displaying a more homogeneous profile. However, because of the limited number of patients, we could not draw a firm conclusion about the correlation between the E5 expression and the disease progression.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21767984     DOI: 10.1016/j.jcv.2011.06.007

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  6 in total

1.  HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy.

Authors:  Francesca Paolini; Gianfranca Curzio; Marcelo Nazario Cordeiro; Silvia Massa; Luciano Mariani; Fulvia Pimpinelli; Antonio Carlos de Freitas; Rosella Franconi; Aldo Venuti
Journal:  Hum Vaccin Immunother       Date:  2016-12-08       Impact factor: 3.452

2.  Immunotherapy in new pre-clinical models of HPV-associated oral cancers.

Authors:  Francesca Paolini; Silvia Massa; Isabella Manni; Rosella Franconi; Aldo Venuti
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

Review 3.  hrHPV E5 oncoprotein: immune evasion and related immunotherapies.

Authors:  Antonio Carlos de Freitas; Talita Helena Araújo de Oliveira; Marconi Rego Barros; Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2017-05-25

4.  Expression of HPV16 E5 down-modulates the TGFbeta signaling pathway.

Authors:  Deborah French; Francesca Belleudi; Maria Vittoria Mauro; Francesca Mazzetta; Salvatore Raffa; Vincenza Fabiano; Antonio Frega; Maria Rosaria Torrisi
Journal:  Mol Cancer       Date:  2013-05-07       Impact factor: 27.401

Review 5.  Papillomavirus E5: the smallest oncoprotein with many functions.

Authors:  Aldo Venuti; Francesca Paolini; Lubna Nasir; Annunziata Corteggio; Sante Roperto; Maria S Campo; Giuseppe Borzacchiello
Journal:  Mol Cancer       Date:  2011-11-11       Impact factor: 27.401

Review 6.  Novel Antigenic Targets of HPV Therapeutic Vaccines.

Authors:  Ditte Rahbæk Boilesen; Karen Nørgaard Nielsen; Peter Johannes Holst
Journal:  Vaccines (Basel)       Date:  2021-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.